Masashi Kondo - Research output - Fujita Health University

View Scopus Profile

h-index

Research activity per year

137 Article
3 Review article
2 Comment/debate
2 Letter
More
- 1 Conference contribution

2 results

Filter

2023
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)
Sugawara, S., Kondo, M., Yokoyama, T., Kumagai, T., Nishio, M., Goto, K., Nakagawa, K., Seto, T., Yamamoto, N., Kudou, K., Asato, T., Zhang, P. & Ohe, Y., 05-2023, In: International Journal of Clinical Oncology. 28, 5, p. 724-725 2 p.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
2022
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)
Sugawara, S., Kondo, M., Yokoyama, T., Kumagai, T., Nishio, M., Goto, K., Nakagawa, K., Seto, T., Yamamoto, N., Kudou, K., Asato, T., Zhang, P. & Ohe, Y., 12-2022, In: International Journal of Clinical Oncology. 27, 12, p. 1839-1840 2 p.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access